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STUDIES ON THE MECHANISM OF THE ANTI-MELANOMA EFFECT OF 
POLYINOSINIC-POL YCYTIDYLIC ACID (PIC) 
II. DECREASED GROWTH OF B-16 MELANOMA FROM PRIOR ExPOSURE TO 
THE TUMOR. ABROGATION OF THIS RESPONSE BY PIC* 
ROBERTS. BART, M.D., ALFRED W. KOPF, M.D. AND STEVEN LAM 
ABSTRACT 
Prior exposure of C-57 black mice to B-16 malignant melanoma inhibi ts the growth of 
subsequent B-16 melanoma implants. Presumably thi s inhibit ion is based on an im-
munologic mechanism. Polyinosin ic-polycyt idylic acid (PIC), given during t he immuniza-
tion period, abrogated the anti-tumor response. 
The experiments failed to support t he hypothesis that the anti-melanoma effect of PIC is 
mediated by an immune response. 
It is possible to suppress the growth of B-16 
malignant melanomas transplanted into C-57 
black mice by prior exposure of the animals to the 
tumor. This suppression is probably based on an 
immune mechanism. We have previously shown 
that polyinosinic-polycytidylic acid (PIC) also in-
hibits the growth of B-16 melanoma in mice [1].1t 
is possible that the PIC inhibition results from 
augmentation of t he host's anti-tumor immune 
response. It seemed logical to assume that if PIC 
inhibited melanoma by augmenting the host's 
anti-tumor immune response, then with PIC we 
might be ab le to boost the inhibition of melanoma 
growth produced by prior exposu re of the host to 
melanoma. 
The experiments described in this report were 
designed to see whether t he ant i-melanoma effect 
of PIC resulted from augmentation of the anti-
tumor immune response of the mice. 
MATEHIALS AND METHODS 
The origina l B-16 malignant melanoma arose spon-
taneously in a C-57 black mouse in 1954 [2] and has been 
carried subsequently in culture as well as in female and 
male C-57 mice. 
Two experiments were done. The first was designed to 
determine whether prior exposure of C-57 mice to B-16 
melanoma resulted in diminished growth of subsequent ly 
implanted B-16 melanomas. The second experiment was 
carried out to see whether PIC would augment the 
anti-tumor effect documented in Experiment I. 
In both experiments fema le C-57 /6J black mice were 
used, and the B-16 malignant melanoma was processed 
and t ransplanted as follows. Excised tumors were 
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pressed through a metal mesh to remove fibrous tissue 
and to separate the tumor cells. The strained melanomas 
were mixed with a sma ll amount of minimal essential 
medium (less than 20 percent of final volume) . A 
13-gauge trochar was used to implant this material 
subcutaneously into the ax illae of the experimental mice. 
Experiment I. Fifteen mice, 5 weeks old, were each 
implanted with 12.5 1'1 of a melanotic melanoma (immu-
nizing implant) into the right axillae on day 0; nineteen 
non-immunized mice served as controls. On day 7 each of 
the 34 mice received 50 1'1 of amelanotic melanoma 
(defi ni t ive implant) into the left axi lla. On day 19 all 
mice were killed and the volumes of the definitive tumors 
in the left axi llae were measured. 
Experiment II. Thirty-four mice, 5 weeks old, received 
immunizing tumor implants of 12.5 1'1 of melanotic 
melanoma on day 0 (Figure). Fifteen were each injected 
in trape ri toneally with 150 meg of PIC in 0.15 ml phos-
phate buffered saline (PBS) on days 1 through 5 (Group 
I); 19 were injected with 0.15 ml PBS alone on the same 
days (G roup II). Thirty-nine mice did not receive immu-
nizing implants. Twenty of these received PIC on days 1 
through 5 (G roup III); 19 received PBS on the same days 
(G roup IV). On day 7 each of the mice in t he four groups 
received a definitive implant of 50 1'1 of melanotic 
malignant melanoma. On day 18 a ll mice were killed and 
the volumes of thei r definitive tumors measured. 
The polyinosinic-polycytidylic ac id (PIC) was pur-
chased from P-L Biochemica ls, Milwaukee. 
RESU LTS 
Experiment I. As shown in Table I, prior expo-
sure of C-57 mice to live implants of B-16 malig-
nant melanoma results in decreased growth of 
subsequently implanted B-16 melanoma. The dif-
ference in average tumor volumes of the definitive 
implants between the immunized and control 
animals (0.36 versus 1.74 ml) was highly significant 
statistica lly (P < 0.001). 
Experiment II. The results of t his experiment 
are shown in Table II. Prior exposure of the mice to 
melanoma aga in resulted in decreased growth of 
subsequent melanoma implants (Group II versus 
Group IV). PIC given during the period of immuni -
zation did not augme nt this response (G roup I 
. versus Group In. In fact, PIC ab rogated the effect 
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FIGURE 1. Protocol of Experiment II. Group I mice (upper row) receive immuni zing B-16 melanoma implant on day 0, 
150 m cgs poly inosini c-polycytidylic ac id (PIC) intra peritonea lly on days 1 to 5, definitive B-16 mela noma transplant 
on day 7, and are sacrifi ced on day 18 fo r measurement of t umor volumes. Group II mi ce a re treated as above but 
receive phosphate buffered sa line (PBS) instead of PIC. Group III and IV do not receive immuni zing implants but are 
otherwise treated like groups I a nd II respectively. 
TABLE I 
Effect of " immunizing" B-16 malignant m elanoma 
implants on the growth of su bsequent m elanoma 
transplants in C-57 mice 
Average 
Group No. of tumor Proba-mice volum e bility* 
(ml) 
Prev iously Exposed to 
M e lanoma {Immunized) 15 0. 36 
< 0.001 
Control 19 1.74 
* P robabili ty using t-test that the difference 111 av-
erage volumes was due to chance. 
of immunization (Group I versus Group IV) . 
When PIC was given to non-immuni zed anima ls 
before definitive transplants, it had no statisti-
cally significant effect on tumor growth (Group 
ITI versus Group IV). 
DISCUSSION 
The results of Experiment I clearly demonstra te 
that prior ex posure of C-57 mice to li ve B-16 
melanoma significantly decreases the growth of 
subsequent transplants of this tumor. It seems 
likely that the observed decreased tumor growth is 
due to an immunologic response on the part of the 
host. 
We also considered the possibility that the 
decreased tumor volumes of the defini tive t rans-
plants could be due to deprivation of nut ri ents 
secondary to the growing " immunizing" implants. 
This possibility was ruled out by a subsequent 
experiment (unpublished data) which showed 
that repeated injections of non-growing X-irradi -
ated melanoma cells also inhibited growth of 
subs~quen t melanoma transplants. In previously 
published work, we showed that when PIC is 
given beginning two days after transplant of B-16 
melanoma the growth of t umors is markedly de-
creased [1]. One explanation for this reduced 
tumor growth was that PIC augmented the host 's 
anti-melanoma immunologic response. We rea-
soned that if this were indeed the mechanism, 
then PIC given during the immunizing period 
would further depress the growth of the defini-
tive transplant as compared to the growth of de-
finitive transplants in animals which had not re-
ceived PIC during the immuni zing period. How-
ever, we found that not only did further suppres-
sion of growth not occur, but that P lC given dur-
ing the immunization period actually cancelled 
the anticipated inhibitory effect of immunization. 
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TABLE II 
Effect of polyinosinic-polycytidylic acid (PIC) during immunization with B-16 malignant melanoma on the growth 
of subsequent melanoma transplants in C-57 mice 
Number of Average tumor P robability• Group 
mice volume (ml) I II lii IV 
I. Immunized plus PIC 15 0.71 
-
< 0.005 0.06 > 0.25 
II. Immunized plus PBS 19 0.49 < 0.005 - < 0.001 < 0.001 
III. Non- immuni zed plus PIC 20 0.87 0.06 < 0.001 - > 0.25 
IV. Non-immunized plus PBS 19 0.78 > 0.25 < 0.001 > 0.25 -
• Probability using t-test that the difference in average volumes was due to chance. 
No statistical difference in average tumor 
volumes was found between the nonimmunized , 
PBS-treated group (Group IV) and the immunized 
PIC-treated group (Group I). 
We do not know how PIC given during the 
immunization period abrogated t he anti-tumor 
response. Among the possibilities a re that PIC 
stimulated blocking antibodies [3] in amounts 
which negated the cell-mediated anti -tumor re-
sponse or that PIC damaged the immunocytes 
directed against t he melanoma. 
Indirect evidence can be marshalled in support 
of both possibilities. Cell-mediated responses and 
circulating antibodies directed against B-16 mela-
noma have been demonstrated [4, 5]. Although 
blocking antibodies to t he B-16 melanoma have 
not been reported, stimulation of cell -bound and 
circulating antibod ies with PIC has been shown 
[6]. 
In doses higher than t hose we used, PIC is 
known to be toxic to lymphoid tissues [7], and 
Fisher et a! demonstrated that mice treated with 
PIC had delayed allograft rejection [8]. Since PIC 
had an inhibitory effect of similar magnitude on 
fibrosarcomas whether they were borne by ir-
radiated or unirradiated mice, these authors con-
cluded that the anti-tumor effect of PIC was by 
direct inhibition of proliferating cells rather than 
by stimulation of immune reactivity. 
On the other hand, Kreider [9] found that when 
rats were rendered immuno-incompetent with thy-
mectomy and anti-lymphocyte serum (as meas-
ured by fai lure of a llograft rejection), PIC did not 
inhibit the growth of the mammary adenocar-
cinomas which they bore. He concluded that the 
loss of anti-tumor effect might have been due to 
loss of cellular immunity against t he tumor or to 
decreased interferon production. 
Our experiments, reported here and elsewhere 
[10], have so far fa iled to support the hypotheses 
that PIC inhibits the growth of B-16 malignant 
melanoma by augmenting the anti-tumor im-
munologic response or by inducing interferon 
production in the C-57 mouse. What is most clear 
from the above experiments, is that when the 
complex events following administration of PIC 
are superimposed upon the complex interrelation-
ships occurring between a host and its tumor, the 
results may not always be predictable. 
Addendum: In a recent. abstract Kreider and 
Benjamin reported that the addition of PIC treat-
ment to C-57 mice receiving X-irradiated B-16 
melanoma cells did not enhance resistance to 
subsequent cha llenge with B-16 cells. (Kreider 
JW, Benjamin SA: Tumor-specific immunity and 
Poly I-Poly C (PIC). Proc Am Assoc Cancer Res 
13:51, 1972) 
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